A groundbreaking clinical trial is set to begin, investigating the effectiveness of conduction system pacing combined with atrioventricular (AV) junction ablation for heart failure patients with atrial fibrillation. Sponsored by Yonsei University, this study aims to evaluate advanced device-based interventions tailored for these complex cardiac conditions. The trial, listed as “YNC AF-HTx” on ClinicalTrials.gov, interfaces technology and research for targeted cardiac care.
What is this study examining?
Heart failure and atrial fibrillation are two increasingly common conditions, often co-occurring in advanced stages. The burdens of these diseases extend to reduced quality of life, complex treatment pathways, and high hospitalization rates. The SYNC AF-HTx trial focuses on determining the safety and performance of left bundle branch pacing (LBBP) combined with AV junction ablation in patients who require implantable cardioverter defibrillators (ICDs).
Two intervention arms are being evaluated: the combined LBBP and AVJ ablation approach paired with ICDs, compared against a standard group with ICD-only therapy. This comparison seeks to provide evidence on whether device therapy improvements may be clinically meaningful.
How does the intervention work?
Conduction system pacing, particularly LBBP, ensures precise cardiac electrical activation, mimicking the heart’s natural pathway. When combined with AV junction ablation, this technique may suppress abnormal electrical signaling from damaged atria, providing therapeutic benefit in atrial fibrillation management. The addition of ICDs may further protect patients at risk of sudden cardiac arrest by delivering life-saving defibrillation.
The trial leverages advancements in medical device technology to assess whether the combined intervention improves heart failure symptoms, reduces atrial fibrillation episodes, and enhances overall cardiac efficiency compared to traditional ICD therapy.
What is the current recruitment status?
The study is listed as “Not yet recruiting” as of the published update. Healthcare professionals enrolled in cardiac and electrophysiology management should monitor the study’s activation via ClinicalTrials.gov to stay informed. The trial identifier is NCT07332871.
Interested clinical sites and professionals are encouraged to connect with Yonsei University for further updates as the trial progresses. Recruitment timelines and eligibility criteria will be essential for providers recommending patients for potential participation.
FAQ
- What is the primary aim of the study?
The study evaluates the safety and efficacy of LBBP combined with AV junction ablation in comparison to ICD-only therapy. - Who can participate?
Specific enrollment criteria will guide participant selection, emphasizing heart failure patients with atrial fibrillation who require ICD therapy. - When does recruitment begin?
Recruitment is currently listed as “not yet recruiting” with no specified start date. - Where will the study be conducted?
The study is sponsored by Yonsei University, and updates on site locations will be available on ClinicalTrials.gov.
Conclusion
The SYNC AF-HTx trial demonstrates how device innovation and patient-specific cardiac interventions continue pushing boundaries in heart failure care. As the clinical trial progresses, detailed insights will aid healthcare and regulatory professionals in optimizing future treatment protocols. Stakeholders should continue monitoring updates to stay informed.
Disclaimer
This content is for informational purposes and does not constitute legal, clinical, or regulatory advice. Medical professionals should consult regulated sources and clinical guidelines.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07332871?term=medical+device